CLINICAL STUDIES OF CANNABIS TOLERANCE
肠外肠内营养指南汇总

附录1肠外肠内营养学临床指南中华医学会肠外肠内营养学分会(2006 版)第一章制定指南的“指南”引言制定指南的初级阶段中华医学会肠外肠内营养学分会(Chinese Society of Parenteral and Enteral Nutrition, CSPEN)于2004年12月在京成立。
作为一个多学科学术组织,CSPEN的愿景(vision)是倡导循证营养支持的实践,促进我国肠外肠内营养的合理应用,为患者提供安全、有效和具有良好效价比的营养治疗。
编写、制定与推广临床指南是实现上述目标的重要途径。
指南定义为:按照循证医学原则,以当前最佳证据为依据,按照系统和规范方法,在多学科专家、各级医院的临床医师和护理人员合作下达成的共识。
本指南的宗旨是为临床医师、护理工作者、营养师、药剂师和患者在特定临床条件下,制定和/或接受肠外肠内营养支持方案提供帮助,并为卫生政策的制定者提供决策依据。
2005年1月- 9月,是我们分会制定指南的初级阶段。
CSPEN常委们在中华医学会的直接指导下,组织了我国肠外肠内营养学工作者及儿科、外科、内科等多学科专家成立了第一届《肠外肠内营养指南》编写委员会。
按照循证医学原则,经过参比国内国外的临床研究报告,制定的肠外肠内营养支持的适应症指南。
在2005年9月在北京召开的的“第一届全国临床营养周”大会上公开征求意见后,又做了大范围的修正和大范围的补充,于当年12月完成了第2005版《肠外肠内营养学临床―指南‖系列一:住院患者肠外营养支持的适应证》。
虽然该指南范围窄,仅是住院患者肠外肠内营养支持的适应证的内容,但仍然受到业者的重视。
已经先后在《中国临床营养杂志》、《中华医学杂志》和《中华外科杂志》等三本核心期刊杂志登载。
发表后受到国内同行的关注,也为2006年完善方法学和扩大内容打下了基础。
一、2006年版指南制订过程在2005年适应症指南的基础上,2006年1月CSPEN《肠外和肠内营养临床指南》编委会和支持小组就启动了文献复习工作,在不同场合广泛听取和收集国内同行意见和建议。
稳定性英文版

HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFLUOXETINE HClC17H18F3NO•HClM.W. = 345.79CAS — 59333-67-4STABILITY INDICATINGA S S A Y V A L I D A T I O NMethod is suitable for:ýIn-process controlþProduct ReleaseþStability indicating analysis (Suitability - US/EU Product) CAUTIONFLUOXETINE HYDROCHLORIDE IS A HAZARDOUS CHEMICAL AND SHOULD BE HANDLED ONLY UNDER CONDITIONS SUITABLE FOR HAZARDOUS WORK.IT IS HIGHLY PRESSURE SENSITIVE AND ADEQUATE PRECAUTIONS SHOULD BE TAKEN TO AVOID ANY MECHANICAL FORCE (SUCH AS GRINDING, CRUSHING, ETC.) ON THE POWDER.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationTABLE OF CONTENTS INTRODUCTION........................................................................................................................ PRECISION............................................................................................................................... System Repeatability ................................................................................................................ Method Repeatability................................................................................................................. Intermediate Precision .............................................................................................................. LINEARITY................................................................................................................................ RANGE...................................................................................................................................... ACCURACY............................................................................................................................... Accuracy of Standard Injections................................................................................................ Accuracy of the Drug Product.................................................................................................... VALIDATION OF FLUOXETINE HCl AT LOW CONCENTRATION........................................... Linearity at Low Concentrations................................................................................................. Accuracy of Fluoxetine HCl at Low Concentration..................................................................... System Repeatability................................................................................................................. Quantitation Limit....................................................................................................................... Detection Limit........................................................................................................................... VALIDATION FOR META-FLUOXETINE HCl (POSSIBLE IMPURITIES).................................. Meta-Fluoxetine HCl linearity at 0.05% - 1.0%........................................................................... Detection Limit for Fluoxetine HCl.............................................................................................. Quantitation Limit for Meta Fluoxetine HCl................................................................................ Accuracy for Meta-Fluoxetine HCl ............................................................................................ Method Repeatability for Meta-Fluoxetine HCl........................................................................... Intermediate Precision for Meta-Fluoxetine HCl......................................................................... SPECIFICITY - STABILITY INDICATING EVALUATION OF THE METHOD............................. FORCED DEGRADATION OF FINISHED PRODUCT AND STANDARD..................................1. Unstressed analysis...............................................................................................................2. Acid Hydrolysis stressed analysis..........................................................................................3. Base hydrolysis stressed analysis.........................................................................................4. Oxidation stressed analysis...................................................................................................5. Sunlight stressed analysis.....................................................................................................6. Heat of solution stressed analysis.........................................................................................7. Heat of powder stressed analysis.......................................................................................... System Suitability stressed analysis.......................................................................................... Placebo...................................................................................................................................... STABILITY OF STANDARD AND SAMPLE SOLUTIONS......................................................... Standard Solution...................................................................................................................... Sample Solutions....................................................................................................................... ROBUSTNESS.......................................................................................................................... Extraction................................................................................................................................... Factorial Design......................................................................................................................... CONCLUSION...........................................................................................................................ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationBACKGROUNDTherapeutically, Fluoxetine hydrochloride is a classified as a selective serotonin-reuptake inhibitor. Effectively used for the treatment of various depressions. Fluoxetine hydrochloride has been shown to have comparable efficacy to tricyclic antidepressants but with fewer anticholinergic side effects. The patent expiry becomes effective in 2001 (US). INTRODUCTIONFluoxetine capsules were prepared in two dosage strengths: 10mg and 20mg dosage strengths with the same capsule weight. The formulas are essentially similar and geometrically equivalent with the same ingredients and proportions. Minor changes in non-active proportions account for the change in active ingredient amounts from the 10 and 20 mg strength.The following validation, for the method SI-IAG-206-02 , includes assay and determination of Meta-Fluoxetine by HPLC, is based on the analytical method validation SI-IAG-209-06. Currently the method is the in-house method performed for Stability Studies. The Validation was performed on the 20mg dosage samples, IAG-21-001 and IAG-21-002.In the forced degradation studies, the two placebo samples were also used. PRECISIONSYSTEM REPEATABILITYFive replicate injections of the standard solution at the concentration of 0.4242mg/mL as described in method SI-IAG-206-02 were made and the relative standard deviation (RSD) of the peak areas was calculated.SAMPLE PEAK AREA#15390#25406#35405#45405#55406Average5402.7SD 6.1% RSD0.1ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::PRECISION - Method RepeatabilityThe full HPLC method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method repeated six times and the relative standard deviation (RSD) was calculated.SAMPLENumber%ASSAYof labeled amountI 96.9II 97.8III 98.2IV 97.4V 97.7VI 98.5(%) Average97.7SD 0.6(%) RSD0.6PRECISION - Intermediate PrecisionThe full method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method was repeated six times by a second analyst on a different day using a different HPLC instrument. The average assay and the relative standard deviation (RSD) were calculated.SAMPLENumber% ASSAYof labeled amountI 98.3II 96.3III 94.6IV 96.3V 97.8VI 93.3Average (%)96.1SD 2.0RSD (%)2.1The difference between the average results of method repeatability and the intermediate precision is 1.7%.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationLINEARITYStandard solutions were prepared at 50% to 200% of the nominal concentration required by the assay procedure. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over the concentration range required. Y-Intercept was found to be insignificant.RANGEDifferent concentrations of the sample (IAG-21-001) for the 20mg dosage form were prepared, covering between 50% - 200% of the nominal weight of the sample.Conc. (%)Conc. (mg/mL)Peak Area% Assayof labeled amount500.20116235096.7700.27935334099.21000.39734463296.61500.64480757797.52000.79448939497.9(%) Average97.6SD 1.0(%) RSD 1.0ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::RANGE (cont.)The results demonstrate linearity as well over the specified range.Correlation coefficient (RSQ)0.99981 Slope11808.3Y -Interceptresponse at 100%* 100 (%) 0.3%ACCURACYACCURACY OF STANDARD INJECTIONSFive (5) replicate injections of the working standard solution at concentration of 0.4242mg/mL, as described in method SI-IAG-206-02 were made.INJECTIONNO.PEAK AREA%ACCURACYI 539299.7II 540599.9III 540499.9IV 5406100.0V 5407100.0Average 5402.899.9%SD 6.10.1RSD, (%)0.10.1The percent deviation from the true value wasdetermined from the linear regression lineHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::ACCURACY OF THE DRUG PRODUCTAdmixtures of non-actives (placebo, batch IAG-21-001 ) with Fluoxetine HCl were prepared at the same proportion as in a capsule (70%-180% of the nominal concentration).Three preparations were made for each concentration and the recovery was calculated.Conc.(%)Placebo Wt.(mg)Fluoxetine HCl Wt.(mg)Peak Area%Accuracy Average (%)70%7079.477.843465102.27079.687.873427100.77079.618.013465100.0101.0100%10079.6211.25476397.910080.8011.42491799.610079.6011.42485498.398.6130%13079.7214.90640599.413080.3114.75632899.213081.3314.766402100.399.618079.9920.10863699.318079.3820.45879499.418080.0820.32874899.599.4Placebo, Batch Lot IAG-21-001HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION OF FLUOXETINE HClAT LOW CONCENTRATIONLINEARITY AT LOW CONCENTRATIONSStandard solution of Fluoxetine were prepared at approximately 0.02%-1.0% of the working concentration required by the method SI-IAG-206-02. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over this range.ACCURACY OF FLUOXETINE HCl AT LOW CONCENTRATIONThe peak areas of the standard solution at the working concentration were measured and the percent deviation from the true value, as determined from the linear regression was calculated.SAMPLECONC.µg/100mLAREA FOUND%ACCURACYI 470.56258499.7II 470.56359098.1III 470.561585101.3IV 470.561940100.7V 470.56252599.8VI 470.56271599.5(%) AverageSlope = 132.7395299.9SD Y-Intercept = -65.872371.1(%) RSD1.1HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSystem RepeatabilitySix replicate injections of standard solution at 0.02% and 0.05% of working concentration as described in method SI-IAG-206-02 were made and the relative standard deviation was calculated.SAMPLE FLUOXETINE HCl AREA0.02%0.05%I10173623II11503731III10103475IV10623390V10393315VI10953235Average10623462RSD, (%) 5.0 5.4Quantitation Limit - QLThe quantitation limit ( QL) was established by determining the minimum level at which the analyte was quantified. The quantitation limit for Fluoxetine HCl is 0.02% of the working standard concentration with resulting RSD (for six injections) of 5.0%. Detection Limit - DLThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected. The detection limit of Fluoxetine HCl is about 0.01% of the working standard concentration.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION FOR META-FLUOXETINE HCl(EVALUATING POSSIBLE IMPURITIES)Meta-Fluoxetine HCl linearity at 0.05% - 1.0%Relative Response Factor (F)Relative response factor for Meta-Fluoxetine HCl was determined as slope of Fluoxetine HCl divided by the slope of Meta-Fluoxetine HCl from the linearity graphs (analysed at the same time).F =132.7395274.859534= 1.8Detection Limit (DL) for Fluoxetine HClThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected.Detection limit for Meta Fluoxetine HCl is about 0.02%.Quantitation Limit (QL) for Meta-Fluoxetine HClThe QL is determined by the analysis of samples with known concentration of Meta-Fluoxetine HCl and by establishing the minimum level at which the Meta-Fluoxetine HCl can be quantified with acceptable accuracy and precision.Six individual preparations of standard and placebo spiked with Meta-Fluoxetine HCl solution to give solution with 0.05% of Meta Fluoxetine HCl, were injected into the HPLC and the recovery was calculated.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES].Approx.Conc.(%)Known Conc.(µg/100ml)Area in SpikedSampleFound Conc.(µg/100mL)Recovery (%)0.0521.783326125.735118.10.0521.783326825.821118.50.0521.783292021.55799.00.0521.783324125.490117.00.0521.783287220.96996.30.0521.783328526.030119.5(%) AVERAGE111.4SD The recovery result of 6 samples is between 80%-120%.10.7(%) RSDQL for Meta Fluoxetine HCl is 0.05%.9.6Accuracy for Meta Fluoxetine HClDetermination of Accuracy for Meta-Fluoxetine HCl impurity was assessed using triplicate samples (of the drug product) spiked with known quantities of Meta Fluoxetine HCl impurity at three concentrations levels (namely 80%, 100% and 120% of the specified limit - 0.05%).The results are within specifications:For 0.4% and 0.5% recovery of 85% -115%For 0.6% recovery of 90%-110%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES]Approx.Conc.(%)Known Conc.(µg/100mL)Area in spikedSample Found Conc.(µg/100mL)Recovery (%)[0.4%]0.4174.2614283182.66104.820.4174.2614606187.11107.370.4174.2614351183.59105.36[0.5%]0.5217.8317344224.85103.220.5217.8316713216.1599.230.5217.8317341224.81103.20[0.6%]0.6261.3918367238.9591.420.6261.3920606269.81103.220.6261.3920237264.73101.28RECOVERY DATA DETERMINED IN SPIKED SAMPLESHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::REPEATABILITYMethod Repeatability - Meta Fluoxetine HClThe full method (as described in SI-IAG-206-02) was carried out on the finished drug product representing lot number IAG-21-001-(1). The HPLC method repeated serially, six times and the relative standard deviation (RSD) was calculated.IAG-21-001 20mg CAPSULES - FLUOXETINESample% Meta Fluoxetine % Meta-Fluoxetine 1 in Spiked Solution10.0260.09520.0270.08630.0320.07740.0300.07450.0240.09060.0280.063AVERAGE (%)0.0280.081SD 0.0030.012RSD, (%)10.314.51NOTE :All results are less than QL (0.05%) therefore spiked samples with 0.05% Meta Fluoxetine HCl were injected.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::Intermediate Precision - Meta-Fluoxetine HClThe full method as described in SI-IAG-206-02 was applied on the finished product IAG-21-001-(1) .It was repeated six times, with a different analyst on a different day using a different HPLC instrument.The difference between the average results obtained by the method repeatability and the intermediate precision was less than 30.0%, (11.4% for Meta-Fluoxetine HCl as is and 28.5% for spiked solution).IAG-21-001 20mg - CAPSULES FLUOXETINESample N o:Percentage Meta-fluoxetine% Meta-fluoxetine 1 in spiked solution10.0260.06920.0270.05730.0120.06140.0210.05850.0360.05560.0270.079(%) AVERAGE0.0250.063SD 0.0080.009(%) RSD31.514.51NOTE:All results obtained were well below the QL (0.05%) thus spiked samples slightly greater than 0.05% Meta-Fluoxetine HCl were injected. The RSD at the QL of the spiked solution was 14.5%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSPECIFICITY - STABILITY INDICATING EVALUATIONDemonstration of the Stability Indicating parameters of the HPLC assay method [SI-IAG-206-02] for Fluoxetine 10 & 20mg capsules, a suitable photo-diode array detector was incorporated utilizing a commercial chromatography software managing system2, and applied to analyze a range of stressed samples of the finished drug product.GLOSSARY of PEAK PURITY RESULT NOTATION (as reported2):Purity Angle-is a measure of spectral non-homogeneity across a peak, i.e. the weighed average of all spectral contrast angles calculated by comparing all spectra in the integrated peak against the peak apex spectrum.Purity Threshold-is the sum of noise angle3 and solvent angle4. It is the limit of detection of shape differences between two spectra.Match Angle-is a comparison of the spectrum at the peak apex against a library spectrum.Match Threshold-is the sum of the match noise angle3 and match solvent angle4.3Noise Angle-is a measure of spectral non-homogeneity caused by system noise.4Solvent Angle-is a measure of spectral non-homogeneity caused by solvent composition.OVERVIEWT he assay of the main peak in each stressed solution is calculated according to the assay method SI-IAG-206-02, against the Standard Solution, injected on the same day.I f the Purity Angle is smaller than the Purity Threshold and the Match Angle is smaller than the Match Threshold, no significant differences between spectra can be detected. As a result no spectroscopic evidence for co-elution is evident and the peak is considered to be pure.T he stressed condition study indicated that the Fluoxetine peak is free from any appreciable degradation interference under the stressed conditions tested. Observed degradation products peaks were well separated from the main peak.1® PDA-996 Waters™ ; 2[Millennium 2010]ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFORCED DEGRADATION OF FINISHED PRODUCT & STANDARD 1.UNSTRESSED SAMPLE1.1.Sample IAG-21-001 (2) (20mg/capsule) was prepared as stated in SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 98.5%.SAMPLE - UNSTRESSEDFluoxetine:Purity Angle:0.075Match Angle:0.407Purity Threshold:0.142Match Threshold:0.4251.2.Standard solution was prepared as stated in method SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 100.0%.Fluoxetine:Purity Angle:0.078Match Angle:0.379Purity Threshold:0.146Match Threshold:0.4272.ACID HYDROLYSIS2.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of conc. HCl was added to this solution The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system after filtration.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 98.8%.SAMPLE- ACID HYDROLYSISFluoxetine peak:Purity Angle:0.055Match Angle:0.143Purity Threshold:0.096Match Threshold:0.3712.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask. 20mL Diluent were added. 2mL of conc. HCl were added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 97.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSTANDARD - ACID HYDROLYSISFluoxetine peak:Purity Angle:0.060Match Angle:0.060Purity Threshold:0.099Match Threshold:0.3713.BASE HYDROLYSIS3.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weight into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 99.3%.SAMPLE - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.063Match Angle:0.065Purity Threshold:0.099Match Threshold:0.3623.2.Standard stock solution was prepared as per method SI-IAG-206-02 : About 22mg Fluoxetine HCl was weighed into a 50mL volumetric flask. 20mL Diluent was added. 2mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH=5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease - 99.5%.STANDARD - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.081Match Angle:0.096Purity Threshold:0.103Match Threshold:0.3634.OXIDATION4.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02. An equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent added and the solution sonicated for 10 minutes.1.0mL of 30% H2O2 was added to the solution and allowed to stand for 5 hours, then made up to volume with Diluent, filtered and injected into HPLC system.Fluoxetine peak intensity decreased to 95.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSAMPLE - OXIDATIONFluoxetine peak:Purity Angle:0.090Match Angle:0.400Purity Threshold:0.154Match Threshold:0.4294.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask and 25mL Diluent were added. 2mL of 30% H2O2 were added to this solution which was standing for 5 hours, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity decreased to 95.8%.STANDARD - OXIDATIONFluoxetine peak:Purity Angle:0.083Match Angle:0.416Purity Threshold:0.153Match Threshold:0.4295.SUNLIGHT5.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1hour. The BST was set to 35°C and the ACT was 45°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak decreased to 91.2% and the dark control solution showed assay of 97.0%. The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak was observed at RRT of 1.5 (2.7%).The total percent of Fluoxetine peak with the degradation peak is about 93.9%.SAMPLE - SUNLIGHTFluoxetine peak:Purity Angle:0.093Match Angle:0.583Purity Threshold:0.148Match Threshold:0.825 ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSUNLIGHT (Cont.)5.2.Working standard solution was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1.5 hour. The BST was set to 35°C and the ACT was 42°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak was decreased to 95.2% and the dark control solution showed assay of 99.5%.The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak were observed at RRT of 1.5 (2.3).The total percent of Fluoxetine peak with the degradation peak is about 97.5%. STANDARD - SUNLIGHTFluoxetine peak:Purity Angle:0.067Match Angle:0.389Purity Threshold:0.134Match Threshold:0.8196.HEAT OF SOLUTION6.1.Sample solution of IAG-21-001-(2) (20 mg/capsule) was prepared as in method SI-IAG-206-02 . Equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution was sonicated for 10 minutes and made up to volume with Diluent. 4mL solution was transferred into a suitable crucible, heated at 105°C in an oven for 2 hours. The sample was cooled to ambient temperature, filtered and injected into the HPLC system.Fluoxetine peak was decreased to 93.3%.SAMPLE - HEAT OF SOLUTION [105o C]Fluoxetine peak:Purity Angle:0.062Match Angle:0.460Purity Threshold:0.131Match Threshold:0.8186.2.Standard Working Solution (WS) was prepared under method SI-IAG-206-02 . 4mL of the working solution was transferred into a suitable crucible, placed in an oven at 105°C for 2 hours, cooled to ambient temperature and injected into the HPLC system.Fluoxetine peak intensity did not decrease - 100.5%.ED. N0: 04Effective Date:APPROVED::。
肿瘤退缩分级标准的对比及其在直肠癌诊治中的应用进展

肿瘤退缩分级标准的对比及其在直肠癌诊治中的应用进展中华结直肠疾病电子杂志2016 年12 月第5 卷第6 期Chin J Colorec Dis ( Electronic Edition ) , December 2016,V ol.5, No.6 ·458··述评·肿瘤退缩分级标准的对比及其在直肠癌诊治中的应用进展谭伊诺陈海燕丁克峰丁克峰教授、主任医师、博士生导师。
现任浙江大学医学院附属第二医院院长助理、肿瘤外科副主任、大肠外科病区主任、浙江大学肿瘤研究所副所长。
中国抗癌协会理事,中国抗癌协会大肠癌专业委员会副主任委员,中国医师协会结直肠外科委员会常委兼副秘书长,浙江省抗癌协会肿瘤转移专业委员会主任委员等职务。
长期从事大肠癌综合诊治和大肠癌腹腔镜微创治疗方面的工作,率先在国内提出并开展腹腔镜辅助结直肠癌快速康复治疗模式,规范MDT 模式,协助制定全国《大肠癌诊治规范》,推动我院成为“全国结直肠癌多学科综合治疗先进技术示范推广工程”首批示范医院之一。
主要从事肿瘤转移和肿瘤耐药机制研究,主持并完成国家自然科学基金课题5 项,卫生部课题1 项,省部级课题10 余项,主持临床研究3 项,发表SCI 及国内核心期刊论文50 余篇。
DOI:10.3877/cma.j.issn.2095-3224.2016.06.001基金项目:2014 年中国国家卫生行业公益性基金项目(No.201402015);国家自然科学基金项目(No.81272455,81472664);浙江省重点研发项目(No.2016CG1360721)作者单位:310009杭州,浙江大学医学院附属第二医院肿瘤外科通讯作者:丁克峰,Email:dingkefeng@【摘要】随着新辅助治疗在直肠癌中的规范化推广,肿瘤退缩分级(TRG)标准逐渐引起广泛关注和重视。
多项研究证实TRG 与直肠癌患者新辅助治疗反应、生存预后有一定相关性,在患者生存预测、随访和临床诊疗策略等方面均有应用前景,甚至也有报道考虑将其纳入临床试验替代终点。
我科学家发现导致乳腺癌耐药的新标志物

我科学家发现导致乳腺癌耐药的新标志物
佚名
【期刊名称】《中国医药生物技术》
【年(卷),期】2011(6)4
【摘要】军事医学科学院蛋白质组学国家重点实验室张学敏课题组与解放军总医院韦立新课题组联合攻关,在乳腺癌内分泌治疗的耐药机制研究中取得重大成果,发现炎症调控分子CUEDC2在乳腺癌细胞中过量表达导致了乳腺癌患者对内分泌治疗产生耐药,并深入揭示了CUEDC2诱发耐药的全新分子机制,对于指导临床治疗具有重要意义。
周涛、潘欣和邰艳红作为共同第一作者的研究论文5月16日在国际权威学术期刊《自然医学》在线发表并将于近期正式刊出。
【总页数】1页(P290-290)
【关键词】乳腺癌患者;耐药机制;新标志物;科学家;国家重点实验室;军事医学科学院;内分泌治疗;解放军总医院
【正文语种】中文
【中图分类】R737.9
【相关文献】
1.英美科学家称脐血有助于预测过敏/科学家发现导致孕妇疟疾高发的原因/乳腺癌每年递增3%专家称手术不必"一刀切"/股骨头坏死治疗在我国取得重大突破/我国研制的抗艾中药进入Ⅱ期试验/肝细胞移植手术获得成功 [J],
2.科学家发现导致乳腺癌的绝大多数相关基因突变 [J], 张坛
3.科学家发现导致乳腺癌细胞扩散基因 [J], 无
4.科学家发现导致乳腺癌扩散基因 [J],
5.耐药机制是乳腺癌治疗一个亟待解决的难题我科学家发现导致乳腺癌耐药的新标志物 [J],
因版权原因,仅展示原文概要,查看原文内容请购买。
心脏康健导引功对慢性心力衰竭易损期患者的干预效果

心脏康健导引功对慢性心力衰竭易损期患者的干预效果沈瑞丽,林嘉文,张自秀,孟园园,赵心韵,陈军上海市杨浦区中医医院心病科,上海200000【摘要】目的观察心脏康健导引功对慢性心力衰竭易损期患者的干预效果。
方法选取2020年10月至2022年5月期间上海市杨浦区中医医院心病科收治的66例慢性心力衰竭易损期患者以随机数表法分为观察组和对照组,每组33例。
对照组患者给予常规干预,观察组患者采用心脏康健导引功干预。
两组患者连续干预3个月,干预结束后比较两组患者的心肺功能、心率变异性,并采用6min 步行试验(6MWT)、明尼苏达心力衰竭生活质量评分量表(MLHF-Q)和中医证候积分评估两组患者的预后。
结果干预后,观察组患者的左心室射血分数(LVEF)和每搏输出量(SV)分别为(63.44±6.02)%、(74.93±8.02)mL ,明显高于对照组的(57.03±6.06)%、(66.21±7.61)mL ,差异均有统计学意义(P <0.05);左室舒张末径(LVEDD)和QT 间期离散度(QTd)分别为(46.34±5.01)mm 、(57.22±5.61)ms ,明显低于对照组的(53.71±5.21)mm 、(65.67±6.26)ms ,差异均有统计学意义(P <0.05);干预后,观察组患者的用力肺活量(FVC)、肺泡通气量(V A)和最大呼气中段流量(MMEF)分别为(2.44±0.51)L 、(5.31±0.80)L/min 、(2.28±0.51)L/s ,明显高于对照组的(2.01±0.47)L 、(4.56±0.75)L/min 、(1.90±0.46)L/s ,差异均有统计学意义(P <0.05);干预后,观察组患者的心率变异性指标总标准差(SDNN)、两个相邻RR 间期互差(PNN50)、差值均方根(RMSSD)分别为(132.81±16.51)ms 、(6.81±0.90)%、(43.28±5.51)ms ,明显高于对照组的(121.40±15.47)ms 、(6.12±0.85)%、(36.89±5.46)ms ,差异均有统计学意义(P <0.05);干预后,观察组患者的MLHF-Q 评分、中医证候积分分别为(26.30±3.42)分、(15.00±2.53)分,明显低于对照组的(31.42±5.15)分、(17.55±3.17)分,6MWT 距离为(356.48±49.96)m ,明显长于对照组的(293.48±69.64)m ,差异均有统计学意义(P <0.05)。
使用肿瘤-衍生的树突细胞抑制因子拮抗剂和Toll类受体激动剂的组合治疗癌症的方法[发明专利]
![使用肿瘤-衍生的树突细胞抑制因子拮抗剂和Toll类受体激动剂的组合治疗癌症的方法[发明专利]](https://img.taocdn.com/s3/m/70d09da5336c1eb91b375d8f.png)
专利名称:使用肿瘤-衍生的树突细胞抑制因子拮抗剂和Toll 类受体激动剂的组合治疗癌症的方法
专利类型:发明专利
发明人:A·P·维卡里,C·考克斯
申请号:CN02827598.5
申请日:20021126
公开号:CN1617742A
公开日:
20050518
专利内容由知识产权出版社提供
摘要:树突细胞(DC)在抗原特异性免疫反应中扮演重要角色。
材料和方法被提供用于治疗疾病状态,包括癌症,其通过活化因疾病而对活化刺激表达低反应的宿主的树突细胞。
特别地,提供用于治疗哺乳类癌症的方法,其包括对于该哺乳类给予有效量的肿瘤-衍生的DC抑制因子拮抗剂联合有效量的Toll类受体(TLR)激动剂。
申请人:先灵公司
地址:美国新泽西州
国籍:US
代理机构:中国专利代理(香港)有限公司
更多信息请下载全文后查看。
抗侵袭性真菌感染药物临床评价的考虑要点
抗侵袭性真菌感染药物临床评价的考虑要点Clinical evaluation of anti-fungal agents for the treatment and prophylaxis invasive fungal disease2003年5月 欧盟EMEA发布2010年3月 药审中心组织翻译安斯泰来制药(中国)有限公司翻译药审中心最终核准目 录1.前言和范畴 (4)2.研究设计的一般考虑 (4)2.1随机化对照试验 (4)2.2 其他研究设计 (5)2.2.1 外部或历史对照的应用 (5)2.2.2 非对照研究 (6)2.3 患者招募和随机化 (7)2.4 研究中患者人群的定义 (7)2.4.1 患者选择 (7)2.4.2 诊断的真菌学确证 (7)2.5 治疗方案 (8)2.5.1 新抗真菌药的剂量方案 (8)2.5.1.1 治疗 (8)2.5.1.2 预防 (9)2.5.2 疗程 (8)2.5.3 注射和口服制剂及其转换 (10)2.5.4 随机对照试验中对照药的选择 (11)2.6 结果和疗效指标 (11)2.6.1 结果 (11)2.6.2 疗效指标和主要人群 (11)2.6.3 评价的时间选择 (12)3. 特定类型研究的考虑 (13)3.1 确诊真菌感染的治疗 (13)3.1.1 抗真菌活性谱的考虑 (13)3.1.2 药代动力学特性的考虑 (14)3.2 真菌感染的经验治疗 (14)3.3 高风险患者人群的预防 (15)3.4 难治性病例的抢救治疗 (16)3.5 在儿童和青少年中的研究 (18)4. 安全性评估 (18)4.1 安全谱评估 (18)4.2 数据库大小 (19)抗侵袭性真菌感染药物临床评价的考虑要点1.前言和范畴本考虑要点阐述了用于治疗和预防侵袭性真菌感染新药的临床研发。
在欧盟,大多数侵袭性真菌感染发生在预先存在至少一种潜在疾病的严重虚弱和/或明显免疫抑制的患者中。
熊果酸通过靶向STAT3信号通路对葡聚糖硫酸钠诱导的小鼠溃疡性结肠炎的保护作用(英文)
JKLMNOPQ<"8B<G"RS7TS7US7VS7WKXN7M$0"YTS7US77Z3?7Z0*%TS7US77WMN[M\M\M]MN7W."'B0$^<&%)_S W`X\\MPaB(&G1Pb(1.9B_SP@KXNPc0RSPVdSP@KXNPe(<f0"TSPUSP_d
! "#$%&'#()* +&,&)-(. /&01&- $2 3$41. /.#0)5 647#)0 8$-%)* 90#:&-,#1;5 64<.$45 647#)0 =>?!!@5 /.#0)A B C()'&%; $2 D01&E-)1#:& F&'#(#0&5 647#)0 90#:&-,#1; $2 G-)'#1#$0)* /.#0&,& F&'#(#0&5 64<.$45 647#)0 =>H!BB5 /.#0)A = 647#)0 I&; J)K$-)1$-; $2 D01&E-)1#:& F&'#(#0& #0 L&-#)1-#(,5 647#)0 90#:&-,#1; $2 G-)'#1#$0)* /.#0&,& F&'#(#0&5 64<.$45 647#)0 =>H!BB5
% & ' ( ) * + , - . / B;":
.C;?D.=? B2E4)$*54F M"'0:0";$G&
内镜下减重手术治疗肥胖的研究进展
内镜下减重手术治疗肥胖的研究进展文志勇;刘志平;文剑波【摘要】肥胖在当今社会逐渐成为危害人类健康的重要因素.在治疗肥胖症方面,饮食控制、运动和传统的内科疗法均难以获得稳定的减肥疗效,而外科手术创伤大、改变解剖结构,难以重复及影响美观,难以满足现代人的要求.随着内镜技术的发展,通过自然腔道(口腔-胃)实施减重手术显示出其独特优势.根据内镜下手术的原理,可分为:胃限制性手术、胃-空肠旁路途径、胃空间占用性手术.目前国内实施内镜下减重手术很少.本文对此三种术式、所需内镜装置及国内外应用效果作一综述,以期更多临床医师及群众了解内镜下减重手术的优势.【期刊名称】《赣南医学院学报》【年(卷),期】2018(038)003【总页数】6页(P265-270)【关键词】肥胖症;内镜手术;减重手术【作者】文志勇;刘志平;文剑波【作者单位】赣南医学院,江西赣州341000;赣南医学院基础医学院,江西赣州341000;赣南医学院第六临床学院,江两萍乡337000【正文语种】中文【中图分类】R723.14近年来,随着世界经济的发展,饮食与生活习惯的改变,肥胖症在全球越来越普遍,2012年我国5省市18~60岁肥胖状况调查显示,超重为28.9%,肥胖为6.3%,肥胖趋势明显,成为影响居民健康的重要疾患[1],国外一项2007~2012美国肥胖流行调查显示39.96%男性,29.74%女性为超重,35.04%男性、36.84%女性为肥胖[2],而肥胖相关的高血压、高血脂、糖尿病等越来越被重视[3]。
在治疗肥胖症方面,饮食控制、运动和传统的内科疗法均难以获得稳定的减肥疗效,而外科减重手术难以满足效果及美观的追求,临床上逐渐开展的内镜下减重手术,具有更小创伤,可逆性及可重复性等优势,内镜下减重手术最早可追溯到上世纪80年代在胃内安放自由浮动的橡胶球囊,但在减重效果及并发症都难以达到满意效果,本世纪初随着内镜技术发展及对现有装备进行改进,在狭小胃内空间进行的操作越来越多,overstitch、IOP、endocinch操作系统都能在胃内进行缝合,国内实施减重手术很少。
中国糖尿病药物注射技术指南(2016年版)
·指南与共识·中国糖尿病药物注射技术指南(2016年版)纪立农郭晓蕙黄金姬秋和贾伟平李玲陆菊明单忠艳孙子林田浩明翁建平邢秋玲袁莉章秋张明霞周智广朱大龙邹大进中华糖尿病杂志指南与共识编写委员会序根据2010年全国性糖尿病流行病学调查情况汇总,中国18岁以上成人糖尿病估测患病率为11.6%,而接受治疗的糖尿病患者仅有25.8%,其中能够达到有效血糖控制的患者仅约39.7%[1]。
可见,我国糖尿病患病率虽高,但血糖达标率却较低。
尽管有众多因素影响血糖达标,但即使是已使用胰岛素治疗后3个月及6个月的患者其血糖达标率也仅有36.2%及39.9%[2],而患者对胰岛素注射技术掌握不到位可能是重要原因之一。
胰岛素治疗是实现良好血糖控制的重要手段之一。
胰岛素注射装置、注射技术是使用胰岛素治疗的重要环节。
“2014-2015全球糖尿病患者胰岛素注射技术调查问卷”是第三次全球糖尿病患者胰岛素注射技术近况调查。
该研究从2014年2月持续到2015年6月,共纳入来自41个国家的13298例患者,其中包括3853例中国大陆患者,100例中国台湾患者。
调查结果显示,全球范围内,不规范注射现象普遍存在,而我国糖尿病患者的注射现状更是不容乐观。
与第二次注射技术调查相比,包括注射部位轮换不规范、注射笔用针头的重复使用、注射时手法错误及患者教育不充分等现象依然存在。
这些问题影响了胰岛素治疗的效果,从而导致部分患者血糖控制不达标。
另一方面,在我国,即使是医务人员,对于胰岛素注射技术对血糖控制影响的认识也有限;对于如何规范胰岛素注射,中国的医护工作者和患者在认识上还有较多不足之处。
幸运的是,目前注射技术在糖尿病管理中的重要作用越来越受到全球糖尿病专家的关注。
2015年10月,我有幸参加了在罗马召开的注射与治疗专家推荐论坛,与来自全球54个国家的183名专家共同讨论制订了《胰岛素注射与输注新推荐》[3],大会围绕在解剖学、生理学、病理学、心理学和注射技术等方面展开讨论。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
222
Annals New York Academy of Sciences
by those investigators as withdrawal symptoms or evidence of physical dependence.3% Some of the inconsistency in the preceding reports might be explained by considering what we know about other more well-studied drugs. In a general review of the determinants of tolerance and dependence, Seevers and Deneau make a simple but important point often overlooked or forgotten when discussing cannabis tolerance and dependence.15 They point out that conditions for optimal development of dependence require “continual neuronal exposure” to the drug without interruption. Failure to recognize this requirement has led to “erroneous conclusions from poorly designed experiments.” They were mainly discussing opiates, but the same might be said about cannabis. Other general reviews indicate that with a variety of sedative-hypnotic drugs and opiates continued “around the clock,” chronic intoxication is necessary to most clearly demonstrate abstinence phenomena.1, 15-1‘J Even with opiates, ordinary conditions of clinical or illicit administration are rarely adequate to produce maximal dependence.15 For example, the standard stabilization dose of morphine in the Lexington studies was 200-400 mg per day in four equal doses.’, lB Nowadays, this dose sounds like a rather large one, but in the Lexington studies, it yielded only a midgrade intensity of dependence.’ There appears to be a “safe interval” between doses of opiates and other psychoactive drugs at which tolerance and dependence are not exhibited. This interval may vary from hours to days, depending on the drug, its disposition, and kinetics.’. With any psychoactive drug, there appears to be a certain dose level below which measurable physical dependence does not develop, even after prolonged and repeated administration, and below which tolerance, if evident at all, is minimal. On the other hand, there is virtually no psychoactive drug that has been experimentally tested in what Seevers and Deneau would term “adequate experiments” that does not produce dependence and show tolerance.’, We designed cannabis experiments with optimal conditions for the development of tolerance and dependence. The dosage range was selected to produce a level of intoxication similar to that experienced t the same time, and in contrast to previous research, the dosage schedule maintained this level of intoxication for prolonged periods of time. Other studies reported at this Conference used equivalent cannabis doses.’* For example, the smoked dose consumed by Mendelson et al.’s subjects was in some cases in excess of equivalent oral doses given to our subjects. Though Mendelson et al.’s study used an adequate dose for a well-designed experiment on tolerance and dependence, they used an inappropriate dose schedule.‘5 The subjects in that study tended to distribute their self-selected dosage, so that for fairly long periods of time each day, the “continual neuronal exposure to the drug” was probabty lacking. With proper attention to the factors that produce optimal conditions for the l6 it should not be development of tolerance and dependence to cannabis,’, surprising that both occur quite predictably in man.
* Supported by Grants DA00033 and DA4RG012 and Contract HSM-42-73-181 from the National Institute on Drug Abuse and National Institute of Mental Health Career Scientist Award K02MH32904 to R.T.J.
CLINICAL STUDIES OF CANNABIS TOLERANCE AND DEPENDENCE *
Reese T. Jones, Neal Benowitz, and John Bachman
Department of Psychiatry University of California, San Francisco San Francisco, California 941 43
INTRODUCTION
Statements like cannabis-related “tolerance and physical dependence do not occur” are commonly made in standard pharmacology texts.l The summary report of the National Commission on Marihuana and Drug Abuse, when discussing the “addiction potential” of marijuana concluded that “fact and fancy have become irrationally mixed regarding marijuana’s physiological and psychological properties. Marijuana clearly is not in the same category as heroin insofar as its physiologic and psychological effects are concerned. In a word, cannabis does not lead to physical dependence.” A recent book that describes extensive chronic marijuana studies in man does not even mention the possibility of dependence.3 Yet, after a comprehensive review of various aspects of cannabis tolerance and dependence, Wikler thinks the evidence indicates that both tolerance and dependence can develop in man.4 For some years, we and others have noted, in outpatient studies, that very frequent cannabis users show diminished drug effects when compared to less frequent users,5- though not all investigators agree.? Such indirect evidence of tolerance, of course, could be explained by several alternate hypotheses : personality or genetic differences, other drug use, and so on. Clinical reports of an abstinence syndrome associated with cannabis use are rare. Occasionally, very frequent cannabis users tested in our laboratories have reported the sudden onset of irritability, restlessness, insomnia, and perspiration after cessation of regular use.s Other investigators have reported similar signs and symptoms in small groups of cannabis users and in primates after prolonged high doses of c a n n a b i ~ . ~ - l ~ reports from outpatients should Such be viewed with some skepticism because of the possibility that these symptoms represent withdrawal from other drugs or concurrent illness. Possible species differences in drug response make the animal data open to question. Williams et al. reported several years ago that experimental subjects given frequent doses of cannabis or synhexyl compound reported a jittery feeling, insomnia, decreased appetite, weight loss, and autonomic symptoms when the experimental drug administration was suddenly st0pped.1~ In more recent studies of chronic marijuana smoking, Mendelson et d ’ s experimental subjects experienced rapid weight loss, decreased appetite, tremor, increased urine specific gravity, and irritability after a 21-day period of frequent marijuana smoking. However, the signs and symptoms were not interpreted